{
    "nctId": "NCT00461136",
    "title": "An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Male patient from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria)"
                    },
                    {
                        "type": "variable",
                        "value": "Female patient from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria)"
                    },
                    {
                        "type": "variable",
                        "value": "Incipient diabetic nephropathy (urinary albumin excretion \u2265 100 mg/day but \u2264 2000 mg/day)"
                    },
                    {
                        "type": "variable",
                        "value": "Established diabetic nephropathy (urinary albumin excretion \u2265 100 mg/day but \u2264 2000 mg/day)"
                    },
                    {
                        "type": "variable",
                        "value": "Glomerular filtration rate (GFR) \u2265 40 ml/min (estimated using Modification of Diet in Renal Disease (MDRD) formula) in the last 4 months"
                    },
                    {
                        "type": "variable",
                        "value": "Female patient must be postmenopausal"
                    },
                    {
                        "type": "variable",
                        "value": "Female patient must have had a bilateral oophorectomy at least 6 months prior to screening"
                    },
                    {
                        "type": "variable",
                        "value": "Female patient must have been surgically sterilized at least 6 months prior to screening"
                    },
                    {
                        "type": "variable",
                        "value": "Female patient must have been hysterectomized at least 6 months prior to screening"
                    },
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Patient on ongoing hypertensive therapy must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1)"
                            },
                            {
                                "type": "variable",
                                "value": "Patient must be on stable antihypertensive medications for at least 8 weeks prior to baseline (Day -1)"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Newly diagnosed hypertensive patient must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1)"
                    },
                    {
                        "type": "variable",
                        "value": "Patient must be on stable hypoglycemic medications for at least 8 weeks prior to Visit 2 (Day -1)"
                    },
                    {
                        "type": "variable",
                        "value": "Patient must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study"
                    },
                    {
                        "type": "variable",
                        "value": "Oral body temperature within the range 35.0-37.5 \u00b0C"
                    },
                    {
                        "type": "variable",
                        "value": "Able to provide written informed consent prior to study participation"
                    },
                    {
                        "type": "variable",
                        "value": "Able to communicate well with the investigator and comply with the requirements of the study"
                    },
                    {
                        "type": "variable",
                        "value": "Minimum age of 30 Years"
                    },
                    {
                        "type": "variable",
                        "value": "Maximum age of 80 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Severe Hypertension Grade 3 WHO classification (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg)"
                            },
                            {
                                "type": "variable",
                                "value": "Acetylsalicyclic acid (ASA) treatment >1g/day or regular use of Non steroidal anti-inflammatory drug (NSAIDs)"
                            },
                            {
                                "type": "variable",
                                "value": "Kidney disease not caused by diabetes or hypertension"
                            },
                            {
                                "type": "variable",
                                "value": "Serum potassium < 3.5 or > 5.1 mEq/L"
                            },
                            {
                                "type": "variable",
                                "value": "GFR < 40 ml/min/1.73m2 as measured by the MDRD formula"
                            },
                            {
                                "type": "variable",
                                "value": "Serum albumin < 2.0mg/dL"
                            },
                            {
                                "type": "variable",
                                "value": "History of hypertensive encephalopathy or cerebrovascular accident at any time prior to Visit 1"
                            },
                            {
                                "type": "variable",
                                "value": "Current diagnosis of heart failure (New York Heart Association (NYHA) Class II-IV)"
                            },
                            {
                                "type": "variable",
                                "value": "History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1"
                            },
                            {
                                "type": "variable",
                                "value": "Second or third degree heart block without a pacemaker"
                            },
                            {
                                "type": "variable",
                                "value": "Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia"
                            },
                            {
                                "type": "variable",
                                "value": "Clinically significant valvular heart disease"
                            },
                            {
                                "type": "variable",
                                "value": "Type 1 diabetes mellitus"
                            },
                            {
                                "type": "variable",
                                "value": "Uncontrolled Type II diabetes mellitus (Hemaglobin subtype A1C (HbA1C) >11 %)"
                            },
                            {
                                "type": "variable",
                                "value": "History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years"
                            },
                            {
                                "type": "variable",
                                "value": "Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation"
                            },
                            {
                                "type": "variable",
                                "value": "Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing"
                            },
                            {
                                "type": "variable",
                                "value": "Significant illness within the two weeks prior to dosing"
                            },
                            {
                                "type": "variable",
                                "value": "History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection"
                            },
                            {
                                "type": "variable",
                                "value": "Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit 1"
                            },
                            {
                                "type": "variable",
                                "value": "Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1"
                            },
                            {
                                "type": "variable",
                                "value": "Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase"
                            },
                            {
                                "type": "variable",
                                "value": "Evidence of hepatic disease, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt"
                            },
                            {
                                "type": "variable",
                                "value": "Current treatment with cholestyramine or cholestipol resins"
                            },
                            {
                                "type": "variable",
                                "value": "History of immunocompromise, including a positive HIV test result"
                            },
                            {
                                "type": "variable",
                                "value": "History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result"
                            },
                            {
                                "type": "variable",
                                "value": "History of drug or alcohol abuse within the 12 months prior to dosing"
                            },
                            {
                                "type": "variable",
                                "value": "Persons directly involved in the execution of this protocol"
                            },
                            {
                                "type": "variable",
                                "value": "Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety"
                            },
                            {
                                "type": "variable",
                                "value": "History of noncompliance to medical regimens or unwillingness to comply with the study protocol"
                            },
                            {
                                "type": "variable",
                                "value": "Known or suspected contraindications to the study medications, including history of allergy to Angiotensin converting enzyme (ACE) inhibitors and/or to thiazide diuretics or other sulfonamide derived drug"
                            },
                            {
                                "type": "variable",
                                "value": "Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study"
                            },
                            {
                                "type": "variable",
                                "value": "Use of any prescription drug or over-the-counter (OTC) medication which is prohibited by the protocol"
                            },
                            {
                                "type": "variable",
                                "value": "Patients who previously participated in any Aliskiren study"
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or nursing woman"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Able to communicate well with the investigator and comply with the requirements of the study'), Symbol('Able to provide written informed consent prior to study participation'), Symbol('Established diabetic nephropathy (urinary albumin excretion \u2265 100 mg/day but \u2264 2000 mg/day)'), Symbol('Female patient from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria)'), Symbol('Female patient must be postmenopausal'), Symbol('Female patient must have been hysterectomized at least 6 months prior to screening'), Symbol('Female patient must have been surgically sterilized at least 6 months prior to screening'), Symbol('Female patient must have had a bilateral oophorectomy at least 6 months prior to screening'), Symbol('Glomerular filtration rate (GFR) \u2265 40 ml/min (estimated using Modification of Diet in Renal Disease (MDRD) formula) in the last 4 months'), Symbol('Incipient diabetic nephropathy (urinary albumin excretion \u2265 100 mg/day but \u2264 2000 mg/day)'), Symbol('Male patient from 30-80 years of age with a diagnosis of Type 2 diabetes (WHO criteria)'), Symbol('Maximum age of 80 Years'), Symbol('Minimum age of 30 Years'), Symbol('Newly diagnosed hypertensive patient must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1)'), Symbol('Oral body temperature within the range 35.0-37.5 \u00b0C'), Symbol('Patient must be on stable antihypertensive medications for at least 8 weeks prior to baseline (Day -1)'), Symbol('Patient must be on stable hypoglycemic medications for at least 8 weeks prior to Visit 2 (Day -1)'), Symbol('Patient must be willing and medically able to discontinue all Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study'), Symbol('Patient on ongoing hypertensive therapy must have a blood pressure \u2265 135/85 mm Hg but lower than 170/105 mm Hg at baseline (Day -1)'), Not(Or(Symbol('Acetylsalicyclic acid (ASA) treatment >1g/day or regular use of Non steroidal anti-inflammatory drug (NSAIDs)'), Symbol('Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety'), Symbol('Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase'), Symbol('Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study'), Symbol('Clinically significant valvular heart disease'), Symbol('Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia'), Symbol('Current diagnosis of heart failure (New York Heart Association (NYHA) Class II-IV)'), Symbol('Current treatment with cholestyramine or cholestipol resins'), Symbol('Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1'), Symbol('Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit 1'), Symbol('Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing'), Symbol('Evidence of hepatic disease, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt'), Symbol('GFR < 40 ml/min/1.73m2 as measured by the MDRD formula'), Symbol('History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result'), Symbol('History of drug or alcohol abuse within the 12 months prior to dosing'), Symbol('History of hypertensive encephalopathy or cerebrovascular accident at any time prior to Visit 1'), Symbol('History of immunocompromise, including a positive HIV test result'), Symbol('History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection'), Symbol('History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years'), Symbol('History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1'), Symbol('History of noncompliance to medical regimens or unwillingness to comply with the study protocol'), Symbol('Kidney disease not caused by diabetes or hypertension'), Symbol('Known or suspected contraindications to the study medications, including history of allergy to Angiotensin converting enzyme (ACE) inhibitors and/or to thiazide diuretics or other sulfonamide derived drug'), Symbol('Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation'), Symbol('Patients who previously participated in any Aliskiren study'), Symbol('Persons directly involved in the execution of this protocol'), Symbol('Pregnant or nursing woman'), Symbol('Second or third degree heart block without a pacemaker'), Symbol('Serum albumin < 2.0mg/dL'), Symbol('Serum potassium < 3.5 or > 5.1 mEq/L'), Symbol('Severe Hypertension Grade 3 WHO classification (Mean Sitting Diastolic Blood Pressure (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg)'), Symbol('Significant illness within the two weeks prior to dosing'), Symbol('Type 1 diabetes mellitus'), Symbol('Uncontrolled Type II diabetes mellitus (Hemaglobin subtype A1C (HbA1C) >11 %)'), Symbol('Use of any prescription drug or over-the-counter (OTC) medication which is prohibited by the protocol'))))"
}